• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Global Cord Blood Corporation

    6/22/23 9:11:07 AM ET
    $CO
    Managed Health Care
    Health Care
    Get the next $CO alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-34541
    Issuer: Global Cord Blood Corp
    Exchange: NEW YORK STOCK EXCHANGE LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 48 Fl, Bank of China Tower, 1 Garden Rd
    Central Hong Kong 000000
    Telephone number: 852-3605-8180
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Ordinary Shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-06-22 By Christopher Rances Senior Analyst, Market Watch and Proxy Compliance
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CO
    SEC Filings

    View All

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    2/12/24 5:06:46 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    12/4/23 5:15:19 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    9/29/23 4:33:27 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

    GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

    4/13/23 3:08:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G filed by Global Cord Blood Corporation

    SC 13G - Global Cord Blood Corp (0001467808) (Subject)

    2/14/23 10:23:43 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/3/23 2:38:38 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Leadership Updates

    Live Leadership Updates

    View All

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

    HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

    12/7/21 8:32:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Financials

    Live finance-specific insights

    View All

    Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

    Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

    7/5/22 4:16:00 PM ET
    $CO
    $INCY
    Managed Health Care
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

    Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

    2/28/22 4:16:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

    HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

    2/23/22 7:00:00 AM ET
    $CO
    Managed Health Care
    Health Care